Cipla receives USFDA approval for Ambrisentan
Cipla has received the final USFDA approval for the Abbreviated New Drug Application (ANDA) for their Ambrisentan Tablets, 5 mg and 10 mg. The drug […]
Cipla has received the final USFDA approval for the Abbreviated New Drug Application (ANDA) for their Ambrisentan Tablets, 5 mg and 10 mg. The drug […]
Cipla has received final USFDA approval for Medroxyprogesterone injectable for prevention of pregnancy in the markets of America. The injection Medroxyprogesterone injectable 150mg/million is a […]
Cipla Ltd is planning to set up a pharma unit in Pithampur in Dhar district of Madhya Pradesh. The project involves reviving the old plant […]
Cipla has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Albendazole Tablets in strength of 200mg. The drug Albendazole Tablets 200mg […]
Cipla Ltd has signed an agreement with biotech firm Stempeutics Research for its stem cell therapy product Stempeucel, indicated for treating critical limb ischemia. Under […]
Cipla has received final USFDA approval to market Entecavir tablets used for treatment of Hepatitis B infection. The tablets are generic versions of Bristol-Myers Suibb’s […]
Cipla has received final USFDA approval for its Abbreviated New Drug Application (ANDA) for Darifenacin extended-release tablets. Darifenacin extended-release tablets are AB-rated generic equivalents of […]
Cipla has received final USFDA approval to market generic Bupropion Hydrochloride extended release tablets used for treatment of major depressive disorder through its subsidiary InvaGen […]
Cipla Ltd has launched the generic version of anti-hepatitis drug Ledipasvir-Sofosbuvir in the domestic market. The drug is used for treating hepatitis C virus. About […]
Copyright © 2024 | WordPress Theme by MH Themes